80.91 0.00 (0.00%)
After hours: 5:15PM EST
|Bid||80.80 x 800|
|Ask||80.92 x 800|
|Day's Range||79.29 - 80.94|
|52 Week Range||63.76 - 89.54|
|PE Ratio (TTM)||23.05|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||2.28 (2.83%)|
|1y Target Est||88.64|
On Thursday, Gilead Sciences' (GILD) Kite Pharma unit and S angamo Therapeutics (SGMO) agreed to collaborate on a new form of allogenic oncology cell therapy. (As this blog noted yesterday, allogenic CAR-T ...
Gilead Sciences, Inc. announced today that James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales director and was appointed to his current role in 2016.
Sangamo rocketed north of 10% in premarket trading Thursday after landing a deal with Gilead to collaborate on cancer treatments.
Sangamo Therapeutics Inc.'s gene-editing technology is playing second fiddle to CRISPR no longer. The Richmond-based company (SGMO) Thursday disclosed a deal with Kite, a subsidiary of Foster City-based Gilead Sciences Inc. (GILD), to develop next-generation cell therapies in cancer. The deal is a huge win for Sangamo, whose zinc finger nucleases method for cutting genes at specific points had taken a backseat to CRISPR, a gene-editing tool developed in part at the University of California, Berkeley.
A number of biotech companies, including Gilead Sciences (GILD), have staked a lot on CAR-T therapies for cancer patients. Today, Guggenheim's Tony Butler and his team take a look at the debate about one set of side effects for these treatments, but ultimately they don't think they'll slow the adoption of these options. While the debate continues, Butler writes, investors shouldn't get distracted from the potential for biotechs in this area: He believes that allogeneic CAR-Ts may be a solution to the issue, as they may be a safer option, and sees allogeneic CAR-Ts as potentially "highly disruptive to cell therapy." Gilead is taking an allogeneic CAR-T approach, he notes, although its strategy isn't clear.
The deal is the latest by a major drugmaker looking to develop lucrative gene therapies that have the potential to treat ailments by directly targeting disease-causing genes. Shares of California biotech firm Sangamo jumped more than 20 percent to a 17-year high of $27.30 on Thursday morning. "These are indeed exciting times in the field of genome-editing and gene therapy," Sangamo Chief Executive Officer Sandy Macrae said on a call with analysts.
Gilead Sciences Inc.'s unit Kite has entered an agreement with Sangamo Therapeutics Inc. to collaborate in developing engineered cell therapies to treat cancer. Under the terms of the deal, Kite will use ...
-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology -- SANTA MONICA, Calif. and RICHMOND, Calif. , Feb. 22, ...
Kite, a Gilead Company and Sangamo Therapeutics, Inc. today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD ) ("Gilead"). If you want access to this report ...
Merck fell after a judge tossed a record $2.54 billion verdict it had won against Gilead Sciences over a hepatitis treatment.
Merck & Co. Inc. shares dipped 1.6% in morning trade Tuesday after the company lost a patent case to Gilead Sciences Inc. . Gilead shares rose 0.4% in morning trade. The case, which involves alleged patent ...
Merck & Co. fell after a federal judge tossed a record $2.54 billion verdict it had won against Gilead Sciences Inc. over a hepatitis treatment.
Novartis: What Are the Major Growth Drivers for 2018? On October 31, 2017, Novartis (NVS) announced the submission of a supplemental biologics license application (or sBLA) to the FDA. The sBLA seeks approval for Kymriah as a treatment option for adult patients with relapsed/refractory diffuse large B-cell lymphoma (or r/r DLBCL).
Novartis: What Are the Major Growth Drivers for 2018? On August 30, 2017, Novartis’ (NVS) CAR T-cell therapy, Kymriah, secured approval from the FDA as a treatment option for patients below 25 years of age who have B-cell precursor acute lymphoblastic leukemia (or ALL). This drug, which is developed by the company in collaboration with the University of Pennsylvania, is indicated only in cases when ALL is refractory or has relapsed a second time or more.
Yahoo Finance’s Seana Smith, Rick Newman and Dion Rabouin discuss a new report by the Centers for Medicare and Medicaid Services that finds spending on health will most likely rise by considerably more than inflation or GDP growth.